Gynecological Cancer clinical trials

Explore recruiting gynecological cancer clinical trials.

Recruiting gynecological cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gynecological Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

First-in-human, open-label, multicenter, Phase I/IIa, dose-escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors

Netherlands, Spain, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

Spain, Sweden, Netherlands, Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL) (PR-3000-02-005/213357) Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination- Deficient Stage III/IV Ovarian Cancer

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

Italy, Poland, France, Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpressing FGFR2b

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Indocyanine green to assess vascularity of ileal conduit anastomosis and regulate ureteral resection margins during pelvic exenteration for recurrent/persistent gynecological cancer. A pilot study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Gynecological Cancer trials by city

Gynecological Cancer in Toronto Gynecological Cancer in Vancouver Gynecological Cancer in Montreal Gynecological Cancer in Calgary Gynecological Cancer in Edmonton Gynecological Cancer in Ottawa Gynecological Cancer in Winnipeg Gynecological Cancer in Quebec City Gynecological Cancer in Hamilton Gynecological Cancer in Kitchener Gynecological Cancer in London Gynecological Cancer in Halifax Gynecological Cancer in New York Gynecological Cancer in Los Angeles Gynecological Cancer in Chicago Gynecological Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease